Alvaro
Lassaletta Atienza
Consultor Médico
Novartis (Sweden)
Täby, SueciaPublications in collaboration with researchers from Novartis (Sweden) (1)
2023
-
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600 Mutant Pediatric High-Grade Glioma
Journal of Clinical Oncology, Vol. 41, Núm. 33, pp. 5174-5183